Summit Creek Advisors LLC grew its stake in shares of Novanta Inc. (NASDAQ:NOVT - Free Report) by 21.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,258 shares of the technology company's stock after buying an additional 9,791 shares during the period. Summit Creek Advisors LLC owned 0.16% of Novanta worth $7,194,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of NOVT. Parallel Advisors LLC increased its position in shares of Novanta by 1,426.7% during the first quarter. Parallel Advisors LLC now owns 229 shares of the technology company's stock valued at $29,000 after buying an additional 214 shares during the period. Johnson Financial Group Inc. increased its position in shares of Novanta by 482.1% during the fourth quarter. Johnson Financial Group Inc. now owns 326 shares of the technology company's stock valued at $49,000 after buying an additional 270 shares during the period. GAMMA Investing LLC increased its position in shares of Novanta by 146.0% during the first quarter. GAMMA Investing LLC now owns 401 shares of the technology company's stock valued at $51,000 after buying an additional 238 shares during the period. CWM LLC increased its position in shares of Novanta by 329.8% during the first quarter. CWM LLC now owns 404 shares of the technology company's stock valued at $52,000 after buying an additional 310 shares during the period. Finally, Signaturefd LLC increased its position in shares of Novanta by 80.0% during the first quarter. Signaturefd LLC now owns 414 shares of the technology company's stock valued at $53,000 after buying an additional 184 shares during the period. 98.35% of the stock is currently owned by institutional investors.
Novanta Stock Up 1.6%
NOVT stock opened at $127.21 on Monday. The company has a current ratio of 2.56, a quick ratio of 1.70 and a debt-to-equity ratio of 0.50. The company's 50 day moving average is $126.22 and its 200 day moving average is $130.94. The stock has a market cap of $4.58 billion, a price-to-earnings ratio of 64.90 and a beta of 1.45. Novanta Inc. has a 1-year low of $98.76 and a 1-year high of $187.00.
Novanta (NASDAQ:NOVT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The technology company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.06. The company had revenue of $233.37 million for the quarter, compared to analysts' expectations of $233.34 million. Novanta had a net margin of 7.42% and a return on equity of 15.06%. Novanta's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.74 earnings per share. Sell-side analysts predict that Novanta Inc. will post 3.03 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, Wall Street Zen cut Novanta from a "buy" rating to a "hold" rating in a research report on Saturday.
Get Our Latest Stock Report on NOVT
Novanta Profile
(
Free Report)
Novanta, Inc engages in the provision of core technology solutions to healthcare and advanced industrial original equipment manufacturers. It operates through the following segments: Photonics, Vision, and Precision Motion. The Photonics segment designs, manufactures, and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products.
Recommended Stories
Want to see what other hedge funds are holding NOVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novanta Inc. (NASDAQ:NOVT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novanta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novanta wasn't on the list.
While Novanta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.